Avacta Collaborates with Tempus AI for Cancer Drug Development
Company Announcements

Avacta Collaborates with Tempus AI for Cancer Drug Development

Avacta Group plc (GB:AVCT) has released an update.

Avacta Group plc has entered a strategic collaboration with Tempus AI to enhance its AI-driven drug development in oncology. This partnership will provide Avacta access to Tempus’ extensive datasets for better understanding tumor biology, aiming to optimize its pre|CISION® platform and target specific cancer patient populations. This collaboration reflects Avacta’s commitment to advancing precision medicine and improving outcomes for cancer patients.

For further insights into GB:AVCT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskAvacta Group Advances with Targeted Cancer Therapies
TipRanks UK Auto-Generated NewsdeskAvacta Group Unveils Promising Cancer Therapy Advances
TipRanks UK Auto-Generated NewsdeskAvacta Group PLC Issues New Shares Amid Strategic Shift
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App